Ovid and Gensaic enter strategic CNS collaboration

24 August 2022

Privately-held Gensaic, a company that seeks to reimagine gene therapy, announced today that it has entered into a strategic collaboration agreement with US neurological diseases specialist Ovid Therapeutics (Nasdaq: OVID).

Under the terms of the collaboration, Gensaic will exclusively develop phage-derived gene delivery vehicles for Central Nervous System (CNS) disorders of interest to Ovid.

“The agreement with Ovid marks an exciting first collaboration for Gensaic with a leading biopharmaceutical company,” said Dr Lavi Erisson, co-founder and chief executive of Gensaic. “Ovid’s veteran management team provides a wealth of experience developing and commercializing blockbuster medicines for the world’s leading biopharmaceutical companies. Together, we have the capabilities and academic collaborators to advance this revolutionary gene therapy platform for the brain,” he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK